Citadel Advisors’s Entera Bio ENTX Stock Holding History

Citadel Advisors’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100	Closed	-$170	–	13178
2025 Q1	$170	Buy	+100	New	+$218	﹤0.01%	14314
2024 Q4	–	Sell	-100	Closed	-$190	–	14719
2024 Q3	$190	Buy	+100	New	+$177	﹤0.01%	14078
2023 Q4	–	Sell	-100	Closed	-$73	–	14504
2023 Q3	$73	Buy	+100	New	+$74	﹤0.01%	14173
2023 Q2	–	Sell	-1,000	Closed	-$1.16K	–	14534
2023 Q1	$1.16K	Buy	1,000 +700	+233%	+$699	﹤0.01%	14351
2022 Q4	$219	Buy	+300	New	+$217	﹤0.01%	14724
2022 Q1	–	Sell	-19,900	Closed	-$56K	–	13821
2021 Q4	$56K	Sell	19,900 -24,500	-55%	-$91.8K	﹤0.01%	13182
2021 Q3	$209K	Sell	44,400 -46,400	-51%	-$238K	﹤0.01%	11898
2021 Q2	$543K	Buy	+90,800	New	+$336K	﹤0.01%	9890

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $318M AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

SEIA

Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Citadel Advisors's ENTX Position: Q1 2026 in Review

Citadel Advisors increased its Entera Bio (ENTX) stake by 510% in Q1 2026, buying an estimated $288K and bringing the position to 245,577 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #10688.

Citadel Advisors first reported a position in ENTX in Q3 2020 and has held it in 15 quarters since. The position peaked at $402K in Q2 2021. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

Citadel Advisors held 245,577 shares of Entera Bio worth $273K as of Q1 2026.
Citadel Advisors bought 205,347 Entera Bio shares in Q1 2026, an estimated $288K.
Entera Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10688 holding.
Citadel Advisors first reported a position in Entera Bio in Q3 2020 and has held it in 15 quarters since.
Citadel Advisors's Entera Bio position peaked at $402K in Q2 2021.
26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.